Latest news with #Qure.ai
Business Wire
26-06-2025
- Business
- Business Wire
Qure.ai Recognized Among TIME's 100 Most Influential Companies of 2025
NEW YORK--(BUSINESS WIRE)-- the world's most widely adopted digital health innovator, has been named to TIME's 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights companies making an extraordinary global impact through innovation, ambition, and measurable success. TIME's editorial spotlighted work in advancing diagnostic equity through AI, stating: 'Trained on one of the world's largest data sets, algorithms are as accurate as a radiologist, according to the company, providing crucial insights in rural or developing areas where specialists may not be available. tools have now been deployed in more than 100 countries, and the company has 18 FDA clearances—the greatest number for lung cancer AI in the U.S.—including three new approvals in 2024.' was selected alongside iconic and dynamic brands such as Abbott, Midi Health, Vertex Pharmaceuticals, Function Health, Gilead, CRISPR Therapeutics, NBBJ, and Northwell Health, and is featured in the Pioneer category among health tech AI firms on the 2025 list. Speaking on the recognition, Prashant Warier, CEO and Founder said, 'To be named among TIME's 100 Most Influential Companies is an acknowledgment of a simple but urgent belief: that access to timely, high-quality diagnostics should not depend on where you live. This honor reflects the dedication of our teams and partners across continents, working to close the gap between innovation and impact. This recognition pushes us to keep advancing that future, where care begins long before crisis.' This milestone recognition follows a pivotal year for marked by accelerated momentum in the United States. With over 18 FDA-cleared findings and the launch of its Lung Cancer Care Continuum, a portfolio of AI solutions to detect, measure, and manage lung nodules; now offers an end-to-end suite that supports earlier lung cancer diagnosis across diverse care settings. Backed by a strategic Series D round led by global investors including Lightspeed, 360 One Asset, and the Merck Global Health Innovation Fund, the company is scaling its commercial and clinical impact worldwide. On the global front, continues to lead in innovation for low- and middle-income countries, drawing on its deep experience in TB surveillance at scale. Its newest offering, Aira, a multi-disease clinical AI co-pilot, was launched at the World Health Assembly in Geneva to support care coordination in resource-constrained settings. To compile this year's TIME100 list, TIME's editors evaluated nominees across sectors based on impact, innovation, ambition, and success, after polling its global network of journalists and outside experts. The final list spotlights 105 companies helping chart a path forward for the world. See the full list here: About is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical conditions to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.
&w=3840&q=100)
Business Standard
17-06-2025
- Business
- Business Standard
Quadria Group announces HealthQuad Fund III with $300 million corpus
Private equity firm Quadria Group on Tuesday announced the launch of HealthQuad Fund III, with a target corpus of $200 million and a $100 million in greenshoe option. HealthQuad Fund III succeeds Funds I and II, which have supported over 18 healthcare companies, including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. Quadria Group is aiming to raise $300 million (about Rs 2,550 crore) for its HealthQuad Fund III. Quadria Group has retained a large part of the existing investment and investment committee team members, who will continue to be involved in the existing portfolio investments, a company statement said. It will also add more people to its investing, operating and clinical team. "India presents one of the world's most compelling healthcare investment opportunities, driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care. "With the full ownership of Fund III and expanded leadership, we are better positioned than ever to deliver cross-regional value for our portfolio companies, across South Asia, Southeast Asia, and the GCC, creating an unparalleled platform for health innovation," Amit Varma, co-founder and Investment Committee member, HealthQuad, said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
17-06-2025
- Business
- Time of India
Quadria Group launches third HealthQuad fund with a corpus of $300 million
MUMBAI: Quadria Group, a healthcare-focused private equity platform on Tuesday announced the launch of HealthQuad Fund III, with a proposed raise of up to $300 million. The fund seeks to back healthcare ventures that have significantly expanded access, affordability, and quality of care across India. Funds I and II backed over 18 companies including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. Dr. Amit Varma, Co-founder and Investment Committee member, HealthQuad, said, 'India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care. With the full ownership of Fund III and expanded leadership, we are better positioned than ever to deliver cross-regional value for our portfolio companies, across South Asia, Southeast Asia, and the GCC, creating an unparalleled platform for health innovation. ' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
23-05-2025
- Health
- Time of India
Qure.ai launches AI tool to aid health workers in LMICs
Mumbai: AI solution provider company has introduced AIRA, an AI-powered co-pilot tool for frontline healthcare workers in low- and middle-income countries (LMICs) at the 78th World Health Assembly in Geneva this week. The company states that community health workers spend over 40 per cent of their time on manual data collection, yet many countries still lack sufficient population-level data for decision-making. According to the company, AIRA is designed to ease the burden on healthcare workers by automating symptom and patient history collection, supporting adherence to clinical protocols, and generating population-level health insights . It aims to address key challenges in LMICs, including a projected shortage of 11 million health workers by 2030 and the 17 million preventable deaths that occur annually. 'With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems,' said Prashant Warier, CEO and Founder,
The Print
10-05-2025
- Health
- The Print
Johnson & Johnson Medtech Partners with Qure.ai to Boost Early Detection of Lung Cancer in India
Mumbai (Maharashtra) [India], May 9: Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ, a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 2025¹. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Traditional diagnostic methods often fail to detect lung cancer at an early stage, leading to delays in treatment. Thus, this collaboration between Johnson & Johnson MedTech and marks a significant leap forward. By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech's commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.' Reference: 1. ICMR and NCDIR World Cancer Day 2024, Close the care gap- Addressing cancer care in India, 04th – February – 2024 Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit (ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.
